2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170578
    SIRT2-IN-17 98%
    SIRT2-IN-17 (compound Z18) is a potent SIRT2 inhibitor. SIRT2-IN-17 reduces the expression of α-SMA and p-Smad2/3.
    SIRT2-IN-17
  • HY-170583
    hAChE-IN-10 3058182-98-9 98%
    hAChE-IN-10 (Compound ET11) is the inhibitor for human acetylcholinesterase (AChE) with an IC50 of 6.34 nM. hAChE-IN-10 scavenges free radicals, and exhibits antioxidant activity. hAChE-IN-10 exhibits metal chelating activity, inhibits Cu2+-induced Aβ1-42 aggregation, reduces the formation of amyloid plaques, and exhibits neuroprotective activity. hAChE-IN-10 ameliorates the Scopolamine (HY-N0296)-induced cognitive impairment in mouse models.
    hAChE-IN-10
  • HY-170589
    GPR17 antagonist 1 1574405-61-0 98%
    GPR17 antagonist 1 (compound 978) is a GPR17 antagonist. GPR17 antagonist 1 can be used in the study of diabetes and obesity.
    GPR17 antagonist 1
  • HY-170621
    STAT1/3-IN-1 2958649-56-2 98%
    STAT1/3-IN-1 (Compound 6k) is a STAT1/3 phosphorylation inhibitor. STAT1/3-IN-1 inhibits the phosphorylation and nuclear translocation of STAT1/3. STAT1/3-IN-1 also inhibits inflammatory enzymes iNOS and COX-2. STAT1/3-IN-1 demonstrates anti-inflammatory effect (reduction of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α) without significant cytotoxicity.
    STAT1/3-IN-1
  • HY-170654
    Opioid receptor antagonist 1 1559075-15-8 98%
    Opioid receptor antagonist 1 (Compound 10) is an Orvinol (HY-D0168)-based opioid receptor antagonist. Opioid receptor antagonist 1 has antagonistic activity to the analgesic properties of Morphine.
    Opioid receptor antagonist 1
  • HY-170658
    AChE-IN-80 98%
    AChE-IN-80 (Compound 1) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-80 can inhibit inflammation and the production of reactive oxygen species (ROS) in vitro- cultured neurons and microglia, trigger autophagy responses, and block the propagation of β-amyloid (Aβ) fibrils. AChE-IN-80 possesses antioxidant activity and neuroprotective effects and can be used in the study of Alzheimer's disease.
    AChE-IN-80
  • HY-170687
    AT2R-IN-1 2896132-06-0 98%
    AT2R-IN-1 (A-174) is a AT2R inhibitor, used in the research of neuropathic pain.
    AT2R-IN-1
  • HY-170691
    hAChE/hBuChE-IN-1 98%
    hAChE/hBuChE-IN-1 (compound C2) is a dual inhibitor of cholinesterase with IC50 values of 514 nM and 358 nM for hAChE and hBuChE respectively. hAChE/hBuChE-IN-1 has oral activity and improves cognition and spatial memory.
    hAChE/hBuChE-IN-1
  • HY-170771
    α5-GABAA receptor modulator 1 98%
    α5-GABAA receptor modulator 1 (Compound A-4) is a silencing allosteric modulator (SAM) specifically targeting the a5 subunit of the GABAA receptor, suitable for research into central nervous system (CNS) disorders.
    α5-GABAA receptor modulator 1
  • HY-170789
    H1R ligand-1 19642-70-7 98%
    H1R ligand-1 (Compound fragment 1) is a high-affinity ligand for the human histamine H1 receptor (H1R). H1R ligand-1 can be used as a scaffold to design and synthesize a set of derivatives to explore H1R binding kinetics.
    H1R ligand-1
  • HY-170790
    HZS60 3027529-88-7 98%
    HZS60 is a NMDAR/TRPM4 inhibitor with brain permeability that can improve cerebral ischemia. HZS60 has significant neuroprotective effects on primary neuronal ischemic damage caused by NMDA and oxygen-glucose deprivation/reoxygenation. HZS60 exhibits good pharmacokinetic characteristics and can inhibit cerebral ischemia-reperfusion injury. HZS60 can be used as a potential inhibitor of ischemic stroke.
    HZS60
  • HY-170798
    Monoamine Oxidase B inhibitor 6 101091-29-6 98%
    Monoamine Oxidase B inhibitor 6 (Compound BT5) is a BBB-penetrable, highly selective, reversible and competitive MAO-B inhibitor, with an IC50 of 0.11 μM. Monoamine Oxidase B inhibitor 6 has antioxidant and neuroprotective effects and can be used in the research of neurodegenerative diseases.
    Monoamine Oxidase B inhibitor 6
  • HY-170801
    Anticonvulsant agent 7 98%
    Anticonvulsant agent 7 (Compound 19) is an orally active broad-spectrum anticonvulsant that demonstrates excellent anticonvulsive activity in both the MES (maximal electroshock seizure) and 6 Hz epilepsy modelsmouse.
    Anticonvulsant agent 7
  • HY-170804
    P2X4 antagonist-3 98%
    P2X4 antagonist-3 (Compound 14c) is a P2X4 antagonist with an IC50 value of 1.2 μM. P2X4 antagonist-3 is promising for research of neuroinflammation, chronic pain, and cancer progression.
    P2X4 antagonist-3
  • HY-170811
    DCDQ 27631-29-4 98%
    DCDQ is a potent acetylcholinesterase (AChE) inhibitor. DCDQ shows a strong binding affinity with the 4EY7 protein (binding energy: −8.2 kcal/mol). DCDQ is promising for research of Alzheimer's disease (AD).
    DCDQ
  • HY-170833
    Anticonvulsant agent 8 98%
    Anticonvulsant agent 8 (compound D4) is an anticonvulsant agent that inhibits GABAA currents with ED50 values of 2.23 and 24.60 mg/kg in the maximum electroshock (MES) and pentylenetetrazol (PTZ) tests in mouse models, respectively.
    Anticonvulsant agent 8
  • HY-170864
    BKS3031A 1449771-90-7 98%
    BKS3031A is the inhibitor for αβ-tubulin that binds to the colchicine binding site, and inhibits the microtubule assembly dynamics.
    BKS3031A
  • HY-170898
    Antidepressant agent 8 3066104-04-6 98%
    Antidepressant agent 8 (Compound 1f) is a selective antagonist for the NMDA receptor GluN1/2A with an IC50 of 2.94 μmol/L. Antidepressant agent 8 exhibits antidepressant-like effects in Hydrocortisone (HY-N0583)-induced zebrafish depression model. Antidepressant agent 8 can cross blood-brain barrier.
    Antidepressant agent 8
  • HY-170902
    GABAA receptor modulator-4 98%
    GABAA receptor modulator-4 (Compound 4) is the negative allosteric modulator for GABAA receptor. GABAA receptor modulator-4 inhibits α1β3γ2 GABAA receptor-mediated peak and steady currents with IC50 of 10 μM and 10 μM.
    GABAA receptor modulator-4
  • HY-170903
    GABAA receptor modulator-3 98%
    GABAA receptor modulator-3 (compound 3b) is a positive allosteric modulator (PAM). GABAA receptor modulator-3 inhibits α1β3γ2 GABAAR at peak and steady state currents with IC50s of 671 and 64 μM, respectively.
    GABAA receptor modulator-3
Cat. No. Product Name / Synonyms Application Reactivity